|
Originally published In Press as doi:10.1074/jbc.M212433200 on December 18, 2002
J. Biol. Chem., Vol. 278, Issue 9, 6992-7000, February 28, 2003
Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl
Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2
Gene*
Corinne
Barat and
Michel J.
Tremblay
From the Centre de Recherche en Infectiologie, Hôpital CHUL,
Centre Hospitalier, Universitaire de Québec and Département
de Biologie Médicale, Faculté de Médecine,
Université Laval, Ste-Foy, Québec G1V 4G2, Canada
Protein-tyrosine phosphatase
(PTP) inhibitors are potent activators of T lymphocytes, most likely by
affecting the early steps of T cell receptor (TCR) signaling. We have
analyzed the effect of the PTP inhibitor bisperoxovanadium (bpV) on
expression of the human cyclooxygenase 2 (COX-2) gene, which is induced
following TCR triggering. Here we show that COX-2 promoter activity is
markedly up-regulated following exposure of Jurkat T cells to
bpV(pic). Interestingly enough, treatment of Jurkat cells with
cyclic AMP-elevating agents such as forskolin, in combination with bpV,
resulted in a more important COX-2 transcriptional activation. Such
activation is inhibited by the immunosuppressive drugs FK506 and
cyclosporin A. The two nuclear factor of activated T cells (NFAT)
binding sites located within the COX-2 promoter region are involved in bpV-mediated positive effect on COX-2 promoter. Electromobility shift
assays showed that NFAT1 and activator protein-1 are both translocated to the nucleus following bpV treatment. The active participation of p56lck, ZAP-70,
p36LAT, and calcium in the
bpV-dependent signaling cascade leading to COX-2
transcriptional activation was demonstrated using deficient cell lines
and specific inhibitors. Although several PTPs are most likely targeted
by bpV, our data suggest that the bpV-mediated signaling cascade is
initiated by inhibition of SHP-1, which leads to phosphorylation
of p56lck and ZAP-70 and, ultimately, to NFAT
and activator protein-1 nuclear translocation. These results suggest
that PTP inhibitors can activate COX-2 gene expression in a manner very
similar to the stimulation induced by TCR triggering.
*
This work was supported in part by Grants HOP-14438,
MOP-37781, and HOP-15575 from the Canadian Institute of Health Research HIV/AIDS Research Program (to M. J. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of a Tier 1 Canada Research Chair in Human
Immuno-Retrovirology. To whom correspondence should be addressed:
Laboratoire d'Immuno-Rétrovirologie Humaine, Centre de Recherche
en Infectiologie, RC709, Hôpital CHUL, Centre Hospitalier
Universitaire de Québec, 2705 boul. Laurier, Ste-Foy,
Québec G1V 4G2, Canada. Tel.: 418-654-2705; Fax: 418-654-2212;
E-mail: michel.j.tremblay@crchul.ulaval.ca.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Castaldi, C. Serra, F. Moretti, G. Messina, R. Paoletti, M. Sampaolesi, A. Torgovnick, M. Baiocchi, F. Padula, A. Pisaniello, et al.
Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype
FASEB J,
November 1, 2007;
21(13):
3573 - 3583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-F. Fortin, C. Barat, Y. Beausejour, B. Barbeau, and M. J. Tremblay
Hyper-responsiveness to Stimulation of Human Immunodeficiency Virus-infected CD4+ T Cells Requires Nef and Tat Virus Gene Products and Results from Higher NFAT, NF-{kappa}B, and AP-1 Induction
J. Biol. Chem.,
September 17, 2004;
279(38):
39520 - 39531.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|